Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27

American Journal of Pathology

Volumn 159, Issue 1, 2001, Pages 205-213

  Sánchez Beato, Margarita ^a,c   Sáez, Ana I ^a   Navas, Inmaculada C ^b   Algara, Patrocinio ^b   Mateo, M Sol ^b   Villuendas, Raquel ^a   Camacho, Francisca ^a   Sánchez Aguilera, Abel ^a   Sánchez, Esther ^b   Piris, Miguel A ^a  

^a Molecular Pathology Programme   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c Invest Oncol Carlos III Ctr Nac   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; B CELL LYMPHOMA; CHROMOSOME 9; GENE DELETION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; METHYLATION; MORTALITY; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROMOTER REGION; SURVIVAL; TUMOR SUPPRESSOR GENE;

CELL CYCLE PROTEINS; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE DELETION; GENE SILENCING; GENES, P16; GENES, P53; HUMANS; LYMPHOMA, B-CELL; METHYLATION; MUTATION; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 0035407045     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61686-0     Document Type: Article

References (54)

1. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756
2. Liggett Jr WH, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998, 16:1197-1206
3. Hirama T, Koeffer HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995, 86:841-854
4. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC: Somatic point mutations in the p53 gene of human tumors and cell lines. Nucleic Acids Res 1996, 24:141-146
5. Pollock PM, Pearson JV, Hayward NK: Compilation of somatic mutations of the CDKN2 human cancers: non-random distribution of base substitutions. Genes Chromosom Cancer 1996, 15:77-88
6. Merlo A, Herman JG, Mao L, Lee DJ, Grabielson E, Burger PC, Baylin SB, Sidransky D: 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1:686-692
7. Ruas M, Peters G: The p16INK4A/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998, 1378:115-177
8. Gronbaek K, Nedergaard T, Andersen MK, Thor Strafen P, Guldberg P, Moller P, Zeuthen J, Hansen EN, Hou-Jensen K, Ralfkiaer E: Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 1998, 12:1266-1271
9. Lukas J, Aagaard L, Strauss M, Bartek J: Oncogenic aberrations of p16INK4/cdkn2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res 1995, 55:4818-4823
10. Villuendas R, Pezzella F, Gatter K, Algara P, Sanchez-Beato M, Martinez P, Martinez JC, Muñoz E, Garcia P, Sánchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA: p21 WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21- immunophenotype associated with missense p53 mutations. J Pathol 1997, 181:51-61
11. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez-Delgado B, Martinez P, Piris MA: Absence of microsatellite instability and low frequency of p53 gene mutation in splenic marginal zone lymphoma. Mol Pathol 1998, 51:262-267
12. Villuendas R, Sánchez-Beato M, Martínez JC, Sáez AI, Martinez-Delgado B, García JF, Mateo MS, Sánchez-Verde L, Benítez J, Martínez P, Piris MA: Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am J Pathol 1998, 153:887-897
13. Martínez-Delgado B, Fernandez-Piqueras J, García MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J: Hypermethylation of a 5′CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997, 11:425-428
14. Herman JG, Civin CI, Issa J-P J, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns of inactivation of p15INK4b and p16INK4a characterize the major types of hematological malignancies. Cancer Res 1997, 57:837-841
15. Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernández PL, Montserrat E, Cardesa A, Campo E: p16INK4a gene inactivation by deletions, mutations and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998, 91: 2977-2984
16. Sáez AI, Sánchez E, Sánchez-Beato M, Cruz MA, Chacon I, Muñoz E, Camacho FI, Martinez-Montero JC, Mollejo M, Garcia JF, Piris M: P27KIP1 is abnormally expressed in diffuse large B-cell lymphomas, and is associated with an adverse clinical outcome. Br J Cancer 1999, 80:1427-1434
17. Vrhorac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F: Prognostic significance of the cell cycle inhibitor P27KIP1 in chronic B-cell lymphocytic leukemia. Bood 1998, 91: 4694-4700
18. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G: Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas - prognostic implications. Blood 1998, 92: 770-777
19. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudomi T, Takahashi T: p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 1998, 58:1042-1047
20. Anayama T, Furihata M, Ishikawa T, Ohtsuki Y, Ogoshi S: Positive correlation between p27KIP1 expression and progression of human esophageal squamous cell carcinoma. Int J Cancer 1998, 79:439-443
21. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Sáez AI, Villuendas R, Sánchez-Verde L, García JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 over-expression. p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999, 12:765-772
22. Barnouin K, Fredersdorf S, Eddaoudi A, Mittnacht S, Pan LX, Du MQ, Lu X: Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene 1999, 18:6388-6397
23. Reynisdóttir I, Polyak K, Iavarone A, Massagué J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995. 9:1831-1837
24. Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A: Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ 1996, 7:135-139
25. Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-dependent kinase and titration of p27KIP1 regulated by mitogen-activated protein kinase (MEKI). Proc Natl Acad Sci USA 1998, 95:1091-1096
26. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G: Induced expression of p16INK4a inhibits CDK4- and CDK2-associated kinase activity by reassortmert of cyclin-CDK-inhibitor complexes. Mol Cell Biol 1999, 19:1981-1989
27. Mitra J, Dai CY, Somasundaram K, El-Deiry W, Satyamoorthy K, Herlyn M, Enders GH: Induction of p21WAF1/CIP1 and inhibition of Cdk2 mediated by tumor suppressor p16INK4a. Mol Cell Biol 1999, 19:3916-3928
28. Bagui TK, Jackson RJ, Agrawal D, Pledger WJ: Analysis of cyclin D3-cdk4 complexes in fibroblasts expressing and lacking p27(kip1) and p21. Mol Cell Biol 2000, 20:8748-8757
29. Sanding V, Brand K, Herwing S, Lukas J, Bartek J, Strauss M: Adenovirally transferred p16INK4a/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 1997, 3:313-319
30. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ: p16INK4a, participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 1998, 18:378-387
31. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW: Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 1997, 88:593-602
32. Greenberg R, Chin L, Femino A, Lee KH, Gottlieb GJ, Singer RH, Greider CW, DePinho RA: Short dysfunctional telomeres impair tumorigenesis in the INK4aΔ2/3 cancer-prone mouse. Cell 1999, 97: 515-525
33. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 1994, 7:480-484
34. Levine AJ, Momand J: Tumor suppressor genes: the p53 and gene products. Biochim Biophys Acta 1990, 1032:119-136
35. Gorgoulis V, Zacharatos P, Kotsinas A, Liloglou T, Nyroudi A, Veslemes M, Rassidakis A, Halazonetis T, Meld J, Kittas C: Alterations of the locus p16-Rb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas Relationship with p53 and MDM2 protein expression. Am J Pathol 1998, 153:1749-1765
36. Markl ID, Jones PA: Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998, 58:5348-5353
37. Kinoshita I, Dosaka-Akita H, Mishina T, Akie K, Nishi M, Hiroumi H, Hommura F, Kawakami Y: Altered p16INK4a and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996, 56:5557-5562
38. Pinyol M, Hernandez L, Martinez A, Cobo F, Hernandez S, Bea S, Lopez-Guillermo A, Nayach I, Palacin A, Nadal A, Fernandez PL, Montserrat E, Cardesa A, Campo E: INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000, 156:1987-1996
39. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermenlink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994, 84:1361-1369
40. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo AA, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/ CDKN2 in primary human tumors. Nat Genet 1995, 11:210-212
41. Mateo M, Mollejo M, Villuendas R, Algara P, Sanchez-Beato M, Martinez P, Piris MA: 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999, 154:1583-1589
42. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826
43. Garcia JF, Villuendas R, Algara P, Saez Al, Sanchez-Verde L, Martinez-Montero JC, Martinez P, Piris MA: Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest 1999, 79:1453-1459
44. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocken E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
45. Baur AS, Shaw P, Burri N, Delacrétaz F, Bosman FT, Chaubert P: Frequent methylation silencing of p15Ink4b (MTS2) and p16 Ink4a (MTS1) in B-cell and T-cell lymphomas Blood 1999, 94:1773-1781
46. Drexler HG: Review of alterations of the cyclin dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells Leukemia 1998, 12:845-849
47. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M: Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998, 91:4677-4685
48. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kanada N, Ohtake S, Uike N, Shimazaki CH, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16;MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995, 86:1548-1556
49. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995, 85:893-901
50. Sánchez-Beato M, Sáez Al, Martínez-Montero JC, Mateo MS, Sánchez-Verde L, Villuendas R, Troncone G, Piris MA: Cyclin dependent kinase inhibitor p27kip1 in lymphoid tissue: p27kip1 expression is inversely proportional to the proliferative index. Am J Pathol 1997, 151:151-160
51. Sharpless EN, DePinho RA: The INK4/ARF locus and its two gene products. Curr Opin Genet Dev 1999, 9:22-30
52. Schmitt CA, McCurrach ME, Stanchina E, Wallace-Brodeur RR, Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 1999, 13:2670-2677
53. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Baryek J, Eilers M: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999, 18:5321-5333
54. Perez-Roger I, Kim S-H, Griffiths B, Sewing A Land H: Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27/KIP1 and p21/Cip1. EMBO J 1999, 18:5310-5320